Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1α PARylation in db/db mice.
Hong WangSara KuuselaRita Rinnankoski-TuikkaVincent DumontRim BouslamaUsama Abo RamadanJo WaalerAnni-Maija LindenNai-Wen ChiStefan KraussEija PirinenSanna H LehtonenPublished in: International journal of obesity (2005) (2020)
Our study unravels a novel molecular mechanism whereby pharmacological inhibition of TNKS in obesity and diabetes enhances oxidative metabolism and ameliorates lipid disorder. This happens via tissue-specific PGC-1α-driven transcriptional reprogramming in muscle and WAT, without affecting liver. This highlights inhibition of TNKS as a potential pharmacotherapy for obesity and T2DM.